Although the World Health Organization (WHO) 2017 guidelines only included MLLT3::KMT2A t(9;11)(p21.3;q23) as an AML-specific gene fusion, there are now over 90 different KMT2A fusion partners listed in the 2022 WHO guidelines, with recommendation to label any KMT2A rearrangement as an AML defining aberration. This evidence concerns the gene MLLT3 and acute myeloid leukemia.